Should the frequency of hemolytic-uremic syndrome after gemcitabine therapy be underestimated? Importance of a systematic screening [4];La fréquence du syndrome hémolytique et urémique secondaire à la gemcitabine est-elle sous-estimée? Intérêt d'un dépistage sytématique

Gastroenterologie Clinique et Biologique

Volumn 30, Issue 2, 2006, Pages 332-334

  Desramé, Jérôme ^a   Duvic, Christian ^a   Béchade, Dominique ^a   Bredin, Christian ^a   Raynaud, J J ^a   Defuentes, G ^a   Dourthe, Louis Marie ^a   Algayres, Jean Pierre ^a  

^a University of Paris Descartes   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE;

ANEMIA; ANURIA; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; EDEMA; HEMATURIA; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTENSION; KIDNEY FAILURE; LETTER; MESOTHELIOMA; PANCREAS CANCER; PROTEINURIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 33645536047     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(06)73184-0     Document Type: Article

References (8)

1. Fung MC, Storniolo AM, Nguyen B, Arning M, Brookfield W, Vigil J. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer 1999;85:2023-32.
2. Flombaum CD, Mouradian JA, Casper ES, Erlandson RA, Benedetti F. Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine. Am J Kidney Dis 1999;33:555-62.
3. Serke S, Riess H, Oettle H, Huhn D. Elevated reticulocyte count - a clue to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: a case report. Br J Cancer 1999;79:1519-21.
4. Eckel F, Lersch C, Erdmann J, Schmidt B, Schulte-Frohlinde E. A 42-year-old patient with the hemolytic-uremic syndrome under gemcitabine therapy for an adenocarcinoma of the liver. The hemolytic-uremic syndrome and gemcitabine. Z Gastroenterol 2000;38:593-6.
5. Dilhuydy MS, Delclaux C, Pariente A, De Precigout V, Aparicio M. Syndrome hémolytique et urémique compliquant un traitement au long cours par Gemcitabine. A propos d'un cas, revue de la littérature. Rev Med Interne 2002;23:189-92.
6. Walter RB, Joerger M, Pestalozzi BC. Gemcitabine-associated hemolytic-uremic syndrome. Am J Kidney Dis 2002 ;40:E16.
7. Lhotta K, Kuhr T, Rumpelt HJ, Woll E, Thaler J, Konig P. Thrombotic microangiopathy with renal failure in two patients undergoing gemcitabine chemotherapy. Am J Nephrol 1999 ;19:590-3.
8. Choi M, Woywodt A, Gobel U, Schneider W, Kettritz R. Haemolytic uraemic syndrome after gemcitabine treatment for pancreatic carcinoma. Nephrol Dial Transplant 1999;14:2523-4.